WHAT IF ONE
GENE

Can change your entire world?

At AVROBIO, we aim to halt or reverse disease with a single dose of gene therapy. Our goal is simple and powerful: We aim to enable individuals with genetic disease to live longer — free from disease progression, free from painful and debilitating symptoms and free from the burden of chronic treatment regimens.

We're striving to deliver freedom for life

Illustration helix

OUR FOCUSA highly personalized therapy

Our investigational gene therapies start with the patient’s own stem cells. We are developing these treatments for several serious lysosomal disorders.

Learn about our areas of focus.

illustration plus sign

OUR APPROACHSolving the challenges of gene therapy

We've spent years developing a state-of-the-art platform to optimize gene therapies. We call it plato®.

Get to know plato®.

This block is broken or missing. You may be missing content or you might need to enable the original module.
This block is broken or missing. You may be missing content or you might need to enable the original module.

Our Views The latest on gene therapy from our expert team

Read our insights

Our News Our latest press releases

Nov 24 2020

AVROBIO Announces Closing of Underwritten Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock.

Read More

Nov 19 2020

AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.

Read More

Nov 19 2020

AVROBIO Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.

Read More

See All

Join our team

Work with Us Join our team!

We are all about innovation. Collaboration. Dedication. And a quality we call “smart speed” — moving thoughtfully but with urgency to bring pioneering therapies to individuals living with genetic disease.

Explore careers at AVROBIO

By the numbers

3

countries where we’re conducting clinical trials 

5

disease indications in our pipeline 

30

years of foundational gene therapy science among our management team

ONE
GOAL:

to give individuals with genetic disease freedom for life

You are now leaving AVROBIO’s website.

The third party website to which you will be directed is not affiliated with AVROBIO, and AVROBIO assumes no responsibility for information or statements on third parties’ websites. Thank you for visiting avrobio.com.

Continue to URL Cancel